Literature DB >> 16076249

Lentiviral vectors and antiretroviral intrinsic immunity.

Bastien Mangeat1, Didier Trono.   

Abstract

Multicellular organisms have evolved under relentless attacks from pathogens, and as a consequence have spiked their genomes with numerous genes that serve to thwart these threats, notably through the building of the innate and adaptive arms of the immune system. The innate immune system is by far the most ancient, being found as widely as in plants and Drosophila, while adaptive immunity arose with the emergence of cartilaginous fishes. Innate immunity enters rapidly into the game during the course of an infection and generally involves the recognition by specific cellular receptors of common pathogen-associated patterns to elicit broad defensive responses, mediated in humans by interferons, macrophages, and natural killer cells, amongst others. When innate immunity fails to eradicate the infection quickly, adaptive immune responses enter into play, to generate exquisitely specific defenses to virtually any pathogen, thanks to a quasi-infinite repertoire of nonself receptors and effectors. A specific form of innate immunity, coined "intrinsic immunity," completes this protection by providing a constant, always-on, line of defense, generally through intracellular obstacles to the replication of pathogens. This component of the immune system has gained much attention as it was discovered that it is a cornerstone of the resistance of mammals against retroviruses. One of these newly discovered intracellular molecular weapons, the APOBEC family of proteins, is active against several classes of retroelements. We present here the current state of knowledge on this rapidly evolving field and discuss implications for gene therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16076249     DOI: 10.1089/hum.2005.16.913

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  11 in total

1.  APOBEC3G and HIV-1: strike and counterstrike.

Authors:  Vanessa B Soros; Warner C Greene
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

Review 2.  HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.

Authors:  Viviana Simon; David D Ho; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

3.  APOBEC3G and HIV-1: strike and counterstrike.

Authors:  Vanessa B Soros; Warner C Greene
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

4.  Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells.

Authors:  Ryuta Sakuma; Amber A Mael; Yasuhiro Ikeda
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

Review 5.  Stem cell therapy for inherited metabolic disorders of the liver.

Authors:  Susan Ellor; Thomas Shupe; Bryon Petersen
Journal:  Exp Hematol       Date:  2008-04-02       Impact factor: 3.084

Review 6.  Genomics meets HIV-1.

Authors:  Amalio Telenti; David B Goldstein
Journal:  Nat Rev Microbiol       Date:  2006-10-09       Impact factor: 60.633

Review 7.  Current Trends in Viral Gene Therapy for Human Orthopaedic Regenerative Medicine.

Authors:  Jagadeesh Kumar Venkatesan; Ana Rey-Rico; Magali Cucchiarini
Journal:  Tissue Eng Regen Med       Date:  2019-02-21       Impact factor: 4.169

8.  The Ezrin-radixin-moesin family member ezrin regulates stable microtubule formation and retroviral infection.

Authors:  Juliane Haedicke; Kenia de Los Santos; Stephen P Goff; Mojgan H Naghavi
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

Review 9.  Foamy virus vectors for gene transfer.

Authors:  Grant D Trobridge
Journal:  Expert Opin Biol Ther       Date:  2009-11       Impact factor: 4.388

10.  Endogenous MMTV proviruses induce susceptibility to both viral and bacterial pathogens.

Authors:  Sanchita Bhadra; Mary M Lozano; Shelley M Payne; Jaquelin P Dudley
Journal:  PLoS Pathog       Date:  2006-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.